CY1119371T1 - Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασων - Google Patents
Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασωνInfo
- Publication number
- CY1119371T1 CY1119371T1 CY20171100943T CY171100943T CY1119371T1 CY 1119371 T1 CY1119371 T1 CY 1119371T1 CY 20171100943 T CY20171100943 T CY 20171100943T CY 171100943 T CY171100943 T CY 171100943T CY 1119371 T1 CY1119371 T1 CY 1119371T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- useful
- carbamazole
- tetrahydrocarbazol
- kinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
Αποκαλύπτονται ενώσεις του Χημικού Τύπου (I) όπου: οι δύο διακεκομμένες γραμμές αναπαριστούν είτε δύο μονούς ή δύο διπλούς δεσμούς˙ το Q είναι: το R1 είναι F, Cl, CN, ή CH3˙ το R2 είναι Cl ή CH3˙ το R3 είναι C(CH3)2OH ή CH2CH2OH˙ το Ra είναι Η ή CH3˙ το κάθε ένα R6 είναι ανεξαρτήτως F, CI, CH3, και/ή OCH3, και το n είναι μηδέν, 1, ή 2. Επίσης αποκαλύπτονται μέθοδοι χρήσης τέτοιων ενώσεων ως αναστολείς της κινάσης τυροσίνης του Bruton (Btk), και φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις. Αυτές οι ενώσεις είναι χρήσιμες σε αγωγή, πρόληψη, ή επιβράδυνση της προόδου παθήσεων ή διαταραχών σε μια ποικιλία θεραπευτικών τομέων, όπως είναι οι αυτοάνοσες παθήσεις και η αγγειακή πάθηση.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839141P | 2013-06-25 | 2013-06-25 | |
| PCT/US2014/043978 WO2014210085A1 (en) | 2013-06-25 | 2014-06-25 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119371T1 true CY1119371T1 (el) | 2018-02-14 |
Family
ID=51210830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100943T CY1119371T1 (el) | 2013-06-25 | 2017-09-06 | Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασων |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9334290B2 (el) |
| EP (1) | EP3013814B1 (el) |
| JP (1) | JP6353529B2 (el) |
| KR (1) | KR102346508B1 (el) |
| CN (1) | CN105358546B (el) |
| AR (1) | AR096721A1 (el) |
| AU (1) | AU2014302548B2 (el) |
| BR (1) | BR112015030723A8 (el) |
| CA (1) | CA2916500A1 (el) |
| CL (1) | CL2015003635A1 (el) |
| CY (1) | CY1119371T1 (el) |
| DK (1) | DK3013814T3 (el) |
| EA (1) | EA026729B1 (el) |
| ES (1) | ES2636652T3 (el) |
| HK (1) | HK1223359A1 (el) |
| HR (1) | HRP20171031T1 (el) |
| HU (1) | HUE034460T2 (el) |
| IL (1) | IL243296B (el) |
| LT (1) | LT3013814T (el) |
| MA (1) | MA38648B1 (el) |
| MY (1) | MY176631A (el) |
| PE (1) | PE20160519A1 (el) |
| PH (1) | PH12015502630A1 (el) |
| PL (1) | PL3013814T3 (el) |
| PT (1) | PT3013814T (el) |
| RS (1) | RS56371B1 (el) |
| SI (1) | SI3013814T1 (el) |
| SM (1) | SMT201700422T1 (el) |
| TN (1) | TN2015000529A1 (el) |
| TW (1) | TWI648272B (el) |
| UY (1) | UY35625A (el) |
| WO (1) | WO2014210085A1 (el) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102345381B1 (ko) | 2013-06-25 | 2021-12-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 |
| SG10201903621SA (en) | 2014-10-24 | 2019-05-30 | Bristol Myers Squibb Co | Tricyclic atropisomer compounds |
| EA034931B1 (ru) | 2014-10-24 | 2020-04-08 | Бристол-Майерс Сквибб Компани | Индолкарбоксамидные соединения |
| MX374724B (es) | 2014-10-24 | 2025-03-06 | Bristol Myers Squibb Company | Derivados de carbazol. |
| US10842963B2 (en) | 2016-07-01 | 2020-11-24 | Brio Device, LLC | Intubation stylet with video feed |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| CN110312713B (zh) * | 2016-12-20 | 2022-08-12 | 百时美施贵宝公司 | 用于制备四氢咔唑甲酰胺化合物的方法 |
| US20210113568A1 (en) | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| CA3224945A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| KR20240148839A (ko) * | 2022-02-15 | 2024-10-11 | 에프. 호프만-라 로슈 아게 | 1,2,3,5,6,7-헥사히드로-s-인다센 유도체 제조를 위한 공정 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| EP1812442A2 (en) | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity |
| BRPI0517211B8 (pt) | 2004-12-17 | 2021-05-25 | Glenmark Pharmaceuticals Sa | composto, composição farmacêutica e seu uso. |
| TW200716551A (en) | 2005-03-10 | 2007-05-01 | Cgi Pharmaceuticals Inc | Certain substituted amides, method of making, and method of use thereof |
| JP2009508872A (ja) * | 2005-09-16 | 2009-03-05 | セレネックス， インコーポレイテッド | カルバゾール誘導体 |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8518964B2 (en) | 2005-11-22 | 2013-08-27 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
| RU2009113585A (ru) | 2006-09-11 | 2010-10-20 | Матрикс Лэборетериз Лтд. (In) | Производные дибензофурана в качестве ингибиторов pde-4 и pde-10 |
| JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| WO2009075830A1 (en) | 2007-12-13 | 2009-06-18 | Merck & Co., Inc. | Inhibitors of janus kinases |
| SI2247558T2 (sl) | 2008-02-14 | 2024-10-30 | Eli Lilly And Company | Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| ES2443948T3 (es) * | 2008-12-19 | 2014-02-21 | Bristol-Myers Squibb Company | Compuestos de carbazol carboxamida útiles como inhibidores de quinasas |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| WO2011116867A1 (de) | 2010-03-26 | 2011-09-29 | Merck Patent Gmbh | Benzonaphthyridinamine als autotaxin-inhibitoren |
| EP2582668B1 (en) * | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| CN103429595B (zh) | 2010-11-15 | 2015-10-21 | Viiv保健英国有限公司 | Hiv复制的抑制剂 |
| ES2590491T3 (es) | 2011-05-17 | 2016-11-22 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en active Application Filing
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko active Active
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja not_active Expired - Fee Related
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
- 2014-06-25 SM SM20170422T patent/SMT201700422T1/it unknown
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh active Active
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
- 2016-10-04 HK HK16111549.5A patent/HK1223359A1/zh not_active IP Right Cessation
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-07-05 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119371T1 (el) | Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασων | |
| CY1123395T1 (el) | Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων | |
| CY1125613T1 (el) | 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ | |
| CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| CY1126109T1 (el) | Αναστολεις toy trpc6 | |
| EA201891049A1 (ru) | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 | |
| CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 | |
| EA201790870A1 (ru) | Трициклические атропоизомерные соединения | |
| BR112015031432A2 (pt) | compostos de carbazol carboxamida úteis como inibidores de cinase | |
| MX381458B (es) | Compuestos biciclicos sustituidos. | |
| CY1120608T1 (el) | Φαρμακευτικως δραστικες ενωσεις | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| MX2024006771A (es) | Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida. | |
| EA201990834A1 (ru) | Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний |